Biotech's Brain Game: A New Grant Signals a Shift in CNS Drug Design

SAN FRANCISCO, CA – June 02, 2026

In the high-stakes world of biotechnology, a press release announcing a $1 million grant can sometimes feel like routine business. But the recent non-dilutive funding awarded to Montara Therapeutics by The Michael J. Fox Foundation (MJFF) is anything but routine. It’s a flashing signal, illuminating a strategic shift in how we approach the brain's most devastating diseases and validating a novel platform that aims to drug the previously 'undruggable.'

This isn't just a story about Parkinson's disease, though it offers immense hope to that community. It’s a story about strategic innovation, the kind that redefines the boundaries of what’s possible. Montara, a preclinical-stage company, is betting its future on a sophisticated 'BrainOnly™' platform, and with this second major grant from MJFF in just over a year, it’s clear one of the world's most influential research foundations is buying into the vision.

The Paradox of a Powerful Target

To understand the significance of Montara's approach, one must first grasp a central dilemma in neurodegenerative research. Parkinson's disease is characterized by the toxic buildup of a protein called α-synuclein, which clumps together and methodically destroys brain cells. For years, scientists have known that our cells possess a natural, powerful 'clean-up crew'—a process called autophagy—that can break down and recycle such toxic debris.

One of the most powerful levers to control this process is a protein known as mTOR. Think of mTOR as the master brake on the autophagy system. Inhibit mTOR, and you release the brake, switching the cellular clean-up machinery into high gear. In lab models of Parkinson's, inhibiting mTOR has shown tremendous promise, effectively clearing the α-synuclein aggregates that are at the heart of the disease.

Herein lies the paradox. mTOR is not just a brake in the brain; it’s a fundamental regulator of cell growth, metabolism, and immunity throughout the entire body. Systemically inhibiting it with drugs like rapamycin unleashes a torrent of serious side effects, from immune suppression to impaired wound healing and metabolic chaos. The very power that makes mTOR an attractive target has also made it a dangerous one, effectively walling it off from therapeutic use in neurology. The target was biologically compelling but clinically untouchable.

Montara's 'BrainOnly' Gambit

This is the challenge Montara Therapeutics was built to solve. The company's BrainOnly™ platform is an elegant solution to the problem of systemic toxicity. Instead of a single drug, the platform employs a two-part combination: a therapeutic designed to penetrate the blood-brain barrier and act on its target, paired with a proprietary 'peripheral blocker' that does not enter the brain. This blocker acts as a bodyguard in the rest of the body, preventing the brain-penetrant drug from causing harmful off-target effects.

The result, in theory, is brain-specific pharmacology. It allows a therapy to do its job precisely where needed—in the central nervous system—while the rest of the body remains shielded from its effects. The new MJFF grant will fund the application of this platform to mTOR inhibitors, aiming to finally and safely unleash autophagy to clear toxic proteins in the brains of Parkinson's patients.

"The mTOR pathway is one of the most powerful levers we have for clearing toxic proteins from the brain, and our platform may finally make it safe enough to use," said Nicholas T. Hertz, Ph.D., Founder and CEO of Montara Therapeutics. His statement cuts to the core of the company's value proposition: making powerful biology safely accessible.

The strategy is not a one-trick pony. Montara is already applying the same principle to other neurological diseases, including an epilepsy program for tuberous sclerosis complex (TSC) and a Parkinson's program targeting LRRK2, a genetic driver of the disease. This demonstrates a broader vision to build a pipeline of therapies by systematically unlocking targets once deemed too toxic.

"Our own genome-wide screens in human neurons identified mTOR signaling as one of the key pathways controlling the accumulation of toxic protein aggregates," noted Martin Kampmann, a Professor at UCSF and Scientific Co-Founder of Montara. "Montara's BrainOnly™ platform is the most compelling approach I've seen for solving that problem."

De-Risking Innovation: The MJFF Factor

The Michael J. Fox Foundation's role here cannot be overstated. As a non-profit powerhouse, MJFF strategically deploys capital to accelerate the most promising science, often stepping in where traditional venture capital or pharmaceutical giants might hesitate. By funding Montara's project through its Therapeutics Pipeline Program, the foundation is placing a calculated bet on a high-risk, high-reward approach.

That this is Montara's second grant from the foundation in just over a year speaks volumes. The first, awarded in May 2025, supported the company's LRRK2 inhibitor program. A repeat investment from such a discerning funder signals deep confidence in the underlying platform technology. It is a powerful third-party validation that moves Montara's science from the realm of academic curiosity toward a viable development path.

“While the underlying biology is compelling, challenges related to systemic toxicity have limited progress,” commented Jessica Tome Garcia, a Lead Scientific Program Manager at MJFF. “This work aims to explore approaches that may help address those barriers and advance our understanding.” Her words reflect the foundation’s core mission: methodically breaking down the barriers that stand between scientific discovery and patient therapies.

A New Blueprint for CNS Innovation

Zooming out, the Montara story is emblematic of a larger trend in biotech innovation. The company, founded in 2023, is a product of a vibrant ecosystem that translates breakthrough academic research—in this case, from UCSF—into a commercially viable enterprise. It is backed by a syndicate of specialized and savvy investors, including SV Health Investors’ Dementia Discovery Fund and Two Bear Capital, who understand the long, arduous path of CNS drug development.

With a leadership team helmed by Hertz, who previously guided Mitokinin to a successful acquisition by AbbVie, the company has the scientific and business credibility to execute its ambitious plan. The BrainOnly™ platform isn't just a tool for one disease; it's a potential blueprint for a new playbook in neurology. It offers a potential path forward for countless targets in Alzheimer’s, brain cancer, and other neurological disorders that have been abandoned due to toxicity issues.

If successful, Montara’s collaboration with MJFF will do more than produce a single candidate for Parkinson's disease. It will provide crucial proof-of-concept for a technology that could redefine risk and reward in CNS drug development, potentially unlocking a new generation of therapies for the brain’s most intractable conditions.